Literature DB >> 7535999

Long-term results of laser treatment in the ocular histoplasmosis syndrome.

H L Cummings1, A J Rehmar, W J Wood, R D Isernhagen.   

Abstract

OBJECTIVE: To determine the long-term visual outcome, rate of persistent choroidal neovascularization, and rate of recurrent choroidal neovascularization in eyes undergoing laser photocoagulation for choroidal neovascularization secondary to ocular histoplasmosis syndrome. DESIGN AND PATIENTS: One hundred one eyes with 5 to 16 years of follow-up that presented with choroidal neovascularization secondary to ocular histoplasmosis were retrospectively evaluated. Patients were grouped according to location of choroidal neovascularization and assignment to observation or laser photocoagulation. MAIN OUTCOME MEASURES: Visual acuity outcome and loss for all groups were compared. The rates of persistent and recurrent choroidal neovascularization for the treated eyes were also evaluated.
RESULTS: Visual acuity of 20/40 or better was obtained in 71% of eyes with treated extrafoveal choroidal neovascularization and 68% with treated juxtafoveal choroidal neovascularization. Recurrent choroidal neovascularization was observed in 23% of treated eyes during a mean follow-up of 9.6 years.
CONCLUSION: Results support the long-term benefit of photocoagulation and need for careful follow-up.

Entities:  

Mesh:

Year:  1995        PMID: 7535999     DOI: 10.1001/archopht.1995.01100040081031

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  3 in total

1.  Presumed ocular histoplasmosis in The Netherlands--an area without histoplasmosis.

Authors:  M S Suttorp-Schulten; J G Bollemeijer; P J Bos; A Rothova
Journal:  Br J Ophthalmol       Date:  1997-01       Impact factor: 4.638

2.  Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases.

Authors:  Joachim Wachtlin; Heinrich Heimann; Tim Behme; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-10-11       Impact factor: 3.117

Review 3.  Verteporfin : a review of its use in the management of subfoveal choroidal neovascularisation.

Authors:  Susan J Keam; Lesley J Scott; Monique P Curran
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.